Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods

被引:46
作者
Hershberger, E
Aeschlimann, JR
Moldovan, T
Rybak, MJ
机构
[1] Wayne State Univ, Detroit Receiving Hosp & Univ Hlth Ctr, Dept Pharm Serv, Antiinfect Res Lab, Detroit, MI 48201 USA
[2] Wayne State Univ, Coll Pharm & Allied Hlth Profess, Detroit, MI 48202 USA
[3] Wayne State Univ, Sch Med, Dept Internal Med, Div Infect Dis, Detroit, MI 48201 USA
关键词
D O I
10.1128/AAC.43.3.717
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This in vitro study evaluated the activities of vancomycin, LY333328, and teicoplanin alone and in combination with gentamicin, rifampin, and RP59500 against Staphylococcus aureus isolates with intermediate susceptibilities to vancomycin. Ampicillin-sulbactam and trovafloxacin were also evaluated. LY333328 and ampicillin-sulbactam resulted in bactericidal activity against all isolates. The combination of gentamicin with glycopeptides showed synergistic activity, while rifampin had no added benefit.
引用
收藏
页码:717 / 721
页数:5
相关论文
共 9 条
[1]  
[Anonymous], MORB MORTAL WKLY REP
[2]  
BOYCE JM, 1997, 37 INT C ANT AG CHEM
[3]   SERUM BACTERICIDAL ACTIVITY OF RIFAMPIN IN COMBINATION WITH OTHER ANTIMICROBIAL AGENTS AGAINST STAPHYLOCOCCUS-AUREUS [J].
HACKBARTH, CJ ;
CHAMBERS, HF ;
SANDE, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (04) :611-613
[4]   Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [J].
Hiramatsu, K ;
Hanaki, H ;
Ino, T ;
Yabuta, K ;
Oguri, T ;
Tenover, FC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :135-136
[5]   Vancomycin-gentamicin synergism revisited: Effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus [J].
Mulazimoglu, L ;
Drenning, SD ;
Muder, RR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1534-1535
[6]  
*NAT COMM CLIN LAB, 1997, M7A4 NAT COMM CLIN L
[7]   Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots [J].
Palmer, SM ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :701-705
[8]  
TENOVER FC, 1998, COMMUNICATION
[9]   Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin [J].
Vincent, J ;
Venitz, J ;
Teng, R ;
Baris, BA ;
Willavize, SA ;
Polzer, RJ ;
Friedman, HL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :75-80